New Biocompatible Frameworks: Small-Molecule HOFs Open the Door to Advanced Bio-Applications In a notable advance that bridges chemistry, materials science, and biotechnology, researchers have developed a new class of highly ordered, macroporous frameworks constructed from small, biocompatible molecules. These frameworks — a type of Hydrogen‑bonded Organic Frameworks (HOFs) — combine structural robustness, large pore sizes,…
Clusterin Enhancer Alzheimer’s Therapy: A Small-Molecule Approach Researchers have identified a clusterin enhancer Alzheimer’s therapy based on a small-molecule drug candidate that boosts levels of a naturally protective brain protein and restores memory in Alzheimer’s disease (AD) mouse models. This discovery offers a promising alternative to traditional amyloid- or tau-centric treatment strategies. Why Clusterin…
IGF2BP3 Inhibitor I3IN-002 Shows Promise Against Hard-to-Treat Leukaemia Researchers have identified a small-molecule inhibitor of the RNA-binding protein IGF2BP3 that demonstrates potent anti-leukaemic activity in both cellular and animal models. The compound, I3IN-002, disrupts IGF2BP3–RNA interactions, suppresses leukaemia cell proliferation, and induces apoptosis — representing a major advance in targeting RNA-binding proteins long considered “undruggable.”…